Related Experiment Video
Updated: Feb 11, 2026

Using a Pan-Viral Microarray Assay Virochip to Screen Clinical Samples for Viral Pathogens
Published on: April 27, 2011
Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis
Haesuk Park1, Donghak Jeong2, Pauline Nguyen2
1University of Florida College of Pharmacy, Pharmaceutical Outcomes & Policy, Gainesville, FL, United States of America.
Insights
Hepatitis B virus (HBV) patients faced higher hospitalization costs than Hepatitis C virus (HCV) patients. While HBV patients had a slightly lower mortality rate, their causes and locations of death differed significantly from HCV patients.
Area of Science:
- Hepatology
- Public Health
- Health Economics
Background:
- The economic burden associated with Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections is increasing.
- Understanding the comparative financial and mortality impact of HBV versus HCV is crucial for resource allocation and patient management.
Purpose of the Study:
- To compare hospital admission rates, charges, mortality rates, and causes of death between Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) patients within a US population.
- To analyze the economic and survival outcomes associated with HBV and HCV infections.
Main Methods:
- A retrospective cohort analysis was conducted using the California Office of Statewide Health Planning and Development database from 2006 to 2013.
- Data from 23,891 HBV patients and 148,229 HCV patients were analyzed to compare key health and economic outcomes.
Main Results:
- Hepatitis B virus (HBV) patients incurred significantly higher liver-related hospital charges per person per year compared to Hepatitis C virus (HCV) patients ($123,239 vs $111,837).
- Across the 8-year study period, HBV patients showed a higher mean increase in all-cause and liver-related hospitalization charges compared to HCV patients.
- While the adjusted mortality hazard ratio was slightly lower for HBV patients (0.96), the major causes of death differed, with HBV patients more frequently dying from other malignant neoplasms (35%) compared to HCV patients (20%).
Conclusions:
- Hepatitis B virus (HBV) infection is associated with greater liver-related hospital charges and a higher overall increase in hospitalization costs over time compared to Hepatitis C virus (HCV).
- Although HBV patients experienced slightly lower mortality rates, their patterns of death, including causes and place of death, were distinct from those of HCV patients.
- These findings highlight the significant and differing economic and survival impacts of HBV and HCV infections, necessitating tailored public health and clinical strategies.
Background:
Economic burden of HBV and HCV infection are trending upwards.
Aims:
Compare hepatitis B virus (HBV) and hepatitis C virus (HCV) related hospital admission rates, charges, mortality rates, causes of death in a US population-based study.
Methods:
Retrospective cohort analysis of HBV and HCV patients from the California Office of Statewide Health Planning and Development (2006-2013) database.
Results:
A total of 23,891 HBV and 148,229 HCV patients were identified. Across the 8-year period, the mean increase for all-cause ($1,863 vs $1,388) and liver-related hospitalization charges ($1,175 vs $675) were significantly higher for the HBV cohort compared to the HCV cohort. HBV patients had significantly higher liver-related hospital charges per person per year than HCV patients after controlling for covariates ($123,239 vs $111,837; p = 0.002). Compared to HCV patients, adjusted mortality hazard ratio was slightly lower in HBV patients (relative risk = 0.96; 95% CI 0.94-0.99). The major causes and places of death were different. The three major causes of death for HBV were: other malignant neoplasms (35%), cardiovascular disease/other circulatory disorders (17%), and liver-related disease (15%) whereas for HCV patients were: liver-related disease (22%), other malignant neoplasms (20%), and cardiovascular disease (16%). Regarding the place of death, 53% of HBV patients and 44% of HCV patients died in hospital inpatient, respectively.
Conclusions:
HBV patients incurred higher liver-related hospital charges and higher mean increase for all-cause and liver-related hospitalization charges over the 8-year period compared to HCV patients. HBV patients had slightly lower mortality rate and their major causes and places of death were noticeably different from HCV patients.
Related Concept Videos
Longitudinal Studies
Longitudinal Research
Viral Recombination
Analysis of Population Pharmacokinetic Data
What is Population Genetics?
What are Populations and Communities?

